Skip to main content Skip to main navigation menu Skip to site footer

The molecular mechanisms of secondary osteoporosis: a literature review



Abstract

Osteoporosis is a metabolic bone disorder characterized by low bone mass, microstructural degradation, decreased bone mineral density, and compromised bone strength. It is known as a disorder affecting the older population. However, aging is not the only factor involved. Millions of people with osteoporosis remain undiagnosed and often involve secondary causes. In some studies, it is estimated that approximately 20-30% of postmenopausal women and above 50% of men having secondary osteoporosis. Secondary osteoporosis usually showed no clear clinical manifestations, and thus allow its progression to a fracture. The process of osteoporosis is complex as it involves various factors. This article tries to provide an in-depth review of the problem regarding the mechanisms of secondary osteoporosis and the significance of related risk factors. At the same time, it emphasized the molecular mechanisms of osteoporosis

Keywords: molecular mechanisms osseous resorption osteoblast osteoclast secondary osteoporosis

References

  1. Dolzhenko AT, Sagalovsky S. Cellular and molecular mechanisms of osteoporosis: current concepts and future direction treatment. Mod Rheumatol J. 2016;10(2):56–63. Available from: http://dx.doi.org/10.14412/1996-7012-2016-2-56-63
  2. Catalano A, Martino G, Morabito N, Scarcella C, Gaudio A, Basile G, et al. Pain in Osteoporosis: From Pathophysiology to Therapeutic Approach. Drugs Aging. 2017;34(10):755–65. Available from: http://dx.doi.org/10.1007/s40266-017-0492-4
  3. Drake MT, Clarke BL, Lewiecki EM. The Pathophysiology and Treatment of Osteoporosis. Clin Ther. 2015;37(8):1837–50. Available from: http://dx.doi.org/10.1016/j.clinthera.2015.06.006
  4. Simpson AH, Murray IR. Main differences in osteoporotic fracture models: which should I use? Injury. 2016;47:S15–20. Available from: http://dx.doi.org/10.1016/s0020-1383(16)30004-3
  5. Thysen S, Luyten FP, Lories RJU. Targets, models and challenges in osteoarthritis research. Dis Model Mech. 2015;8(1):17–30. Available from: https://pubmed.ncbi.nlm.nih.gov/25561745
  6. Cauley JA. Osteoporosis. Curr Opin Rheumatol. 2017;29(2):150–6. Available from: http://dx.doi.org/10.1097/bor.0000000000000365
  7. Bouet G, Bouleftour W, Juignet L, Linossier M-T, Thomas M, Vanden-Bossche A, et al. The impairment of osteogenesis in bone sialoprotein (BSP) knockout calvaria cell cultures is cell density dependent. PLoS One. 2015;10(2):e0117402–e0117402. Available from: https://pubmed.ncbi.nlm.nih.gov/25710686
  8. Florencio-Silva R, Sasso GR da S, Sasso-Cerri E, Simões MJ, Cerri PS. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. Biomed Res Int. 2015/07/13. 2015;2015:421746. Available from: https://pubmed.ncbi.nlm.nih.gov/26247020
  9. Gamsjäger M, Resch H. Cathepsin K-Inhibitoren: präklinische und klinische Daten. Wiener Medizinische Wochenschrift. 2015;165(3–4):65–70. Available from: http://dx.doi.org/10.1007/s10354-014-0336-3
  10. Chapurlat RD. Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women. Ther Adv Musculoskelet Dis. 2015;7(3):103–9. Available from: https://pubmed.ncbi.nlm.nih.gov/26029271
  11. Engelke K, Fuerst T, Dardzinski B, Kornak J, Ather S, Genant HK, et al. Odanacatib Treatment Affects Trabecular and Cortical Bone in the Femur of Postmenopausal Women: Results of a Two-Year Placebo-Controlled Trial. J Bone Miner Res. 2014;30(1):30–8. Available from: http://dx.doi.org/10.1002/jbmr.2292
  12. Shiwaku Y, Neff L, Nagano K, Takeyama K-I, de Bruijn J, Dard M, et al. The Crosstalk between Osteoclasts and Osteoblasts Is Dependent upon the Composition and Structure of Biphasic Calcium Phosphates. PLoS One. 2015;10(7):e0132903–e0132903. Available from: https://pubmed.ncbi.nlm.nih.gov/26193362
  13. Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2014/11/29. 2015;26(2):699–712. Available from: https://pubmed.ncbi.nlm.nih.gov/25432773
  14. Rucci N, Teti A. Osteoclasts: Essentials and Methods. In: Principles of Bone and Joint Research. Springer International Publishing; 2017. p. 33–53.
  15. Wang C, Meng H, Wang X, Zhao C, Peng J, Wang Y. Differentiation of Bone Marrow Mesenchymal Stem Cells in Osteoblasts and Adipocytes and its Role in Treatment of Osteoporosis. Med Sci Monit. 2016;22:226–33. Available from: https://pubmed.ncbi.nlm.nih.gov/26795027
  16. Li Y, Jin D, Xie W, Wen L, Chen W, Xu J, et al. PPAR-γ and Wnt Regulate the Differentiation of MSCs into Adipocytes and Osteoblasts Respectively. Curr Stem Cell Res Ther. 2018;13(3):185–92. Available from: http://dx.doi.org/10.2174/1574888x12666171012141908
  17. Zhou Z, Gao M, Liu Q, Tao MDJ. Comprehensive transcriptome analysis of mesenchymal stem cells in elderly patients with osteoporosis. Aging Clin Exp Res. 2015;27(5):595–601. Available from: http://dx.doi.org/10.1007/s40520-015-0346-z
  18. Stains JP, Watkins MP, Grimston SK, Hebert C, Civitelli R. Molecular mechanisms of osteoblast/osteocyte regulation by connexin43. Calcif Tissue Int. 2013/06/11. 2014;94(1):55–67. Available from: https://pubmed.ncbi.nlm.nih.gov/23754488
  19. Hajiyev A, Azizova G, Bayramova N. Catelliside and calprotectine as biomarker in inflammatory process. Mod Achiev Azerbaijan. 2018;2:45–8.
  20. Haciyev A, Osmanov H, Azizova G, Afandiyev A. The level of Calprotectin and main parameters of calcium – phosphorus metabolism in Osteoporosis caused by Rheumatoid Arthritis. In: Eurasia Conference on Chemical Sciences. Rome; 2018. Available from: http://www.eurasia2018.org/rome/poster-sessions
  21. Hadjiyev A, Osmanov H, Efendiyev A. The study of the main parameters of calcium – phosphorus metabolizm and antimicrobial peptide of defensin in osteoporosis caused by rheumatoid arthritis. In: VI International Simposium “Interaction of the nervous and immune systems in health and disease.†Saint Petersburg; 2017.
  22. Huseynov G, Azizova G, Efendiyev A. Quantitative changes in serum IL8, TNF-α and TGF-β1 levels depending on compensation stage in type 2 diabetic patients. Int J Diabetes Metab. 2009;17.
  23. Lee E-J, Kim S-M, Choi B, Kim E-Y, Chung Y-H, Lee E-J, et al. Interleukin-32 Gamma Stimulates Bone Formation by Increasing miR-29a in Osteoblastic Cells and Prevents the Development of Osteoporosis. Sci Rep. 2017;7:40240. Available from: https://pubmed.ncbi.nlm.nih.gov/28079119
  24. Martin TJO. Advances in understanding the molecular basis of bone remodelling: Past, present and future. Bone. 2009;44:S18. Available from: http://dx.doi.org/10.1016/j.bone.2009.01.415
  25. Shi X, Zhang Z. MicroRNA-135a-5p is involved in osteoporosis progression through regulation of osteogenic differentiation by targeting RUNX2. Exp Ther Med. 2019/08/05. 2019;18(4):2393–400. Available from: https://pubmed.ncbi.nlm.nih.gov/31555350

How to Cite

Hajiyev, A., Azizova, G., & Efendiyev, A. (2020). The molecular mechanisms of secondary osteoporosis: a literature review. Bali Medical Journal, 9(2), 562–566. https://doi.org/10.15562/bmj.v9i2.1755
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
1

Total
15

Share

Search Panel

Akif Hajiyev
Google Scholar
Pubmed
BMJ Journal

Gulnara Azizova
Google Scholar
Pubmed
BMJ Journal

Arif Efendiyev
Google Scholar
Pubmed
BMJ Journal